摘要
目的:探讨培菲康联合三联疗法治疗Hp相关性胃溃疡的效果及对患者血清超敏C反应蛋白(hs-CRP)的影响。方法:选取2015年8月-2017年3月因Hp感染性胃溃疡于本院就诊的患者82例,按照随机数字表法将其分为对照组和观察组,各41例。对照组单纯采用三联疗法,观察组在对照组基础上联合培菲康口服治疗。比较两组临床疗效及不良反应发生情况。结果:治疗后,两组总症状积分及hs-CRP均较治疗前降低(P<0.05),且观察组均低于对照组(P<0.05);观察组总有效率为95.12%,高于对照组的85.37%,但差异无统计学意义(P>0.05);观察组Hp清除率为92.68%,高于对照组的75.61%(P<0.05);Hp清除后,观察组复发率为14.63%(6/38),明显低于对照组29.27%(12/31)(P<0.05),观察组不良反应总发生率为9.76%,低于对照组的29.27%(P<0.05)。结论:培菲康联合三联疗法治疗Hp相关性胃溃疡效果显著,可改善黏膜炎症反应,降低复发率,安全可靠,值得推广。
Objective:To investigate the effect of Bifico combined with triple therapy in treatment of Hprelated gastric ulcer and its effect on serum hypersensitive C-reactive protein(hs-CRP)level in patients.Method:82 patients with Hp-related gastric ulcer admitted in our hospital from August 2015 to March 2017 were selected,according to the random number table method,they were divided into control group and observation group,41 cases in each group.The control group was treated with triple therapy,and observation group was combined with Bifico based on control group.The clinical efficacy and adverse reactions were compared between two groups.Result:After treatment,the total symptom scores and hs-CRP of two groups were lower than those of before treatment(P<0.05),and observation group were lower than those of control group(P<0.05).The total effective rate of observation group was 95.12%,which was higher than 85.37%of the control group,the difference was not statistically significant(P>0.05).The clearance rate of Hp in observation group was 92.68%,which was higher than 75.61%in control group(P<0.05).After Hp clearance,the relapse rate of observation group was 14.63%(6/38),which was significantly lower than 29.27%(12/31)of control group(P<0.05).The total incidence of adverse reactions in observation group was 9.76%,which was lower than 29.27%of control group(P<0.05).Conclusion:Bifico combined with triple therapy in treatment of Hp-related gastric ulcer effect is significant,can improve the mucosal inflammation,reduce the recurrence rate,safe and reliable,worthy of promotion.
作者
赵静
易静
ZHAO Jing;YI Jing(The First People’s Hospital of Jiujiang City,Jiujiang 332000,China)
出处
《中国医学创新》
CAS
2017年第33期16-19,共4页
Medical Innovation of China
基金
九江市科技计划项目(2012A2013)